136 related articles for article (PubMed ID: 17117183)
1. Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Beesley AH; Palmer ML; Ford J; Weller RE; Cummings AJ; Freitas JR; Firth MJ; Perera KU; de Klerk NH; Kees UR
Br J Cancer; 2006 Dec; 95(11):1537-44. PubMed ID: 17117183
[TBL] [Abstract][Full Text] [Related]
2. Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic leukemia cell lines, YCUB series, derived from children.
Goto H; Naruto T; Tanoshima R; Kato H; Yokosuka T; Yanagimachi M; Fujii H; Yokota S; Komine H
Leuk Res; 2009 Oct; 33(10):1386-91. PubMed ID: 19157546
[TBL] [Abstract][Full Text] [Related]
3. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines.
Beesley AH; Weller RE; Senanayake S; Welch M; Kees UR
Leuk Res; 2009 Feb; 33(2):321-5. PubMed ID: 18789525
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.
Beesley AH; Palmer ML; Ford J; Weller RE; Cummings AJ; Freitas JR; Firth MJ; Perera KU; de Klerk NH; Kees UR
Br J Haematol; 2007 Apr; 137(2):109-16. PubMed ID: 17391490
[TBL] [Abstract][Full Text] [Related]
5. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
Efferth T; Sauerbrey A; Steinbach D; Gebhart E; Drexler HG; Miyachi H; Chitambar CR; Becker CM; Zintl F; Humeny A
Int J Oncol; 2003 Aug; 23(2):509-17. PubMed ID: 12851703
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
[TBL] [Abstract][Full Text] [Related]
7. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
Styczynski J; Koltan A; Wysocki M
Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
[TBL] [Abstract][Full Text] [Related]
8. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
Estlin EJ; Yule SM; Lowis SP
Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
[TBL] [Abstract][Full Text] [Related]
9. Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia.
Samuels AL; Heng JY; Beesley AH; Kees UR
Br J Haematol; 2014 Apr; 165(1):57-66. PubMed ID: 24456076
[TBL] [Abstract][Full Text] [Related]
10. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
11. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
12. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
13. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
14. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples.
Estes DA; Lovato DM; Khawaja HM; Winter SS; Larson RS
Br J Haematol; 2007 Oct; 139(1):20-30. PubMed ID: 17854304
[TBL] [Abstract][Full Text] [Related]
19. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.
Fine BM; Kaspers GJ; Ho M; Loonen AH; Boxer LM
Cancer Res; 2005 Jan; 65(1):291-9. PubMed ID: 15665306
[TBL] [Abstract][Full Text] [Related]
20. Selective apoptosis of natural killer-cell tumours by l-asparaginase.
Ando M; Sugimoto K; Kitoh T; Sasaki M; Mukai K; Ando J; Egashira M; Schuster SM; Oshimi K
Br J Haematol; 2005 Sep; 130(6):860-8. PubMed ID: 16156856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]